Your browser doesn't support javascript.
Implications of SARS-CoV-2 Infection in Systemic Juvenile Idiopathic Arthritis.
Ailioaie, Laura Marinela; Ailioaie, Constantin; Litscher, Gerhard.
  • Ailioaie LM; Department of Medical Physics, Alexandru Ioan Cuza University, 11 Carol I Boulevard, 700506 Iasi, Romania.
  • Ailioaie C; Department of Medical Physics, Alexandru Ioan Cuza University, 11 Carol I Boulevard, 700506 Iasi, Romania.
  • Litscher G; Research Unit of Biomedical Engineering in Anesthesia and Intensive Care Medicine, Research Unit for Complementary and Integrative Laser Medicine, Traditional Chinese Medicine (TCM) Research Center Graz, Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Auenbruggerplatz 39, 8036 Graz, Austria.
Int J Mol Sci ; 23(8)2022 Apr 12.
Article in English | MEDLINE | ID: covidwho-1785752
ABSTRACT
Systemic juvenile idiopathic arthritis (sJIA) is a serious multifactorial autoinflammatory disease with a significant mortality rate due to macrophage activation syndrome (MAS). Recent research has deepened the knowledge about the pathophysiological mechanisms of sJIA-MAS, facilitating new targeted treatments, and biological disease-modifying antirheumatic drugs (bDMARDs), which significantly changed the course of the disease and prognosis. This review highlights that children are less likely to suffer severe COVID-19 infection, but at approximately 2-4 weeks, some cases of multisystem inflammatory syndrome in children (MIS-C) have been reported, with a fulminant course. Previous established treatments for cytokine storm syndrome (CSS) have guided COVID-19 therapeutics. sJIA-MAS is different from severe cases of COVID-19, a unique immune process in which a huge release of cytokines will especially flood the lungs. In this context, MIS-C should be reinterpreted as a special MAS, and long-term protection against SARS-CoV-2 infection can only be provided by the vaccine, but we do not yet have sufficient data. COVID-19 does not appear to have a substantial impact on rheumatic and musculoskeletal diseases (RMDs) activity in children treated with bDMARDs, but the clinical features, severity and outcome in these patients under various drugs are not yet easy to predict. Multicenter randomized controlled trials are still needed to determine when and by what means immunoregulatory products should be administered to patients with sJIA-MAS with a negative corticosteroid response or contraindications, to optimize their health and safety in the COVID era.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Arthritis, Juvenile / Antirheumatic Agents / Macrophage Activation Syndrome / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines Limits: Child / Humans Language: English Year: 2022 Document Type: Article Affiliation country: Ijms23084268

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Arthritis, Juvenile / Antirheumatic Agents / Macrophage Activation Syndrome / COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines Limits: Child / Humans Language: English Year: 2022 Document Type: Article Affiliation country: Ijms23084268